Myeloid/lymphoid neoplasms with FGFR1 rearrangement

Paolo Strati; Guilin Tang; Dzifa Y. Duose; Saradhi Mallampati; Rajyalakshmi Luthra; Keyur P. Patel; Mohammad Hussaini; Abu Sayeef Mirza; Rami S. Komrokji; Stephen Oh; John Mascarenhas; Vesna Najfeld; Vivek Subbiah; Hagop Kantarjian; Guillermo Garcia-Manero; Srdan Verstovsek; Naval Daver

doi:10.1080/10428194.2017.1397663

Myeloid/lymphoid neoplasms with FGFR1 rearrangement

Paolo Strati, Guilin Tang, Dzifa Y. Duose, Saradhi Mallampati, Rajyalakshmi Luthra, Keyur P. Patel, Mohammad Hussaini, Abu Sayeef Mirza, Rami S. Komrokji, Stephen Oh, John Mascarenhas, Vesna Najfeld, Vivek Subbiah, Hagop Kantarjian, Guillermo Garcia-Manero, Srdan Verstovsek, Naval Daver

Research output: Contribution to journal › Article › peer-review

51 Scopus citations

Abstract

Myeloid/lymphoid neoplasms with FGFR1 rearrangement are a rare entity. We present a multicenter experience of 17 patients with FISH-confirmed FGFR1 rearrangement. The clinical presentation at diagnosis included myeloproliferative neoplasm (MPN) in 4 (24%) patients, acute leukemia (AL) in 7 (41%), and concomitant MPN with AL in 6 (35%). The two most frequently observed cytogenetic abnormalities were t(8;13)(p11.2;q12)(partner gene ZMYM2) and t(8;22)(p11.2; q11.2)(BCR). Seventy-eight percent of tested patients had a RUNX1 mutation, of whom all had AL. Overall response rate to frontline therapy was 69%, and 76% of patients subsequently received allogeneic stem cell transplant (ASCT). After a median follow-up of 11 months, median progression-free survival was 15 months and median overall survival was not reached. In conclusion, FGFR1-rearranged hematologic malignancies present with features of MPN and/or AL. FGFR1 and RUNX1 are therapeutic targets for ongoing and future clinical trials.

Original language	English
Pages (from-to)	1672-1676
Number of pages	5
Journal	Leukemia and Lymphoma
Volume	59
Issue number	7
DOIs	https://doi.org/10.1080/10428194.2017.1397663
State	Published - Jul 3 2018

Keywords

FGFR1 rearrangement
Myeloproliferative neoplasm
RUNX1
acute leukemia

Access to Document

10.1080/10428194.2017.1397663

Cite this

Strati, P., Tang, G., Duose, D. Y., Mallampati, S., Luthra, R., Patel, K. P., Hussaini, M., Mirza, A. S., Komrokji, R. S., Oh, S., Mascarenhas, J., Najfeld, V., Subbiah, V., Kantarjian, H., Garcia-Manero, G., Verstovsek, S., & Daver, N. (2018). Myeloid/lymphoid neoplasms with FGFR1 rearrangement. Leukemia and Lymphoma, 59(7), 1672-1676. https://doi.org/10.1080/10428194.2017.1397663

@article{762dc5518c9d4b56bd64909e09cf294a,

title = "Myeloid/lymphoid neoplasms with FGFR1 rearrangement",

abstract = "Myeloid/lymphoid neoplasms with FGFR1 rearrangement are a rare entity. We present a multicenter experience of 17 patients with FISH-confirmed FGFR1 rearrangement. The clinical presentation at diagnosis included myeloproliferative neoplasm (MPN) in 4 (24%) patients, acute leukemia (AL) in 7 (41%), and concomitant MPN with AL in 6 (35%). The two most frequently observed cytogenetic abnormalities were t(8;13)(p11.2;q12)(partner gene ZMYM2) and t(8;22)(p11.2; q11.2)(BCR). Seventy-eight percent of tested patients had a RUNX1 mutation, of whom all had AL. Overall response rate to frontline therapy was 69%, and 76% of patients subsequently received allogeneic stem cell transplant (ASCT). After a median follow-up of 11 months, median progression-free survival was 15 months and median overall survival was not reached. In conclusion, FGFR1-rearranged hematologic malignancies present with features of MPN and/or AL. FGFR1 and RUNX1 are therapeutic targets for ongoing and future clinical trials.",

keywords = "FGFR1 rearrangement, Myeloproliferative neoplasm, RUNX1, acute leukemia",

author = "Paolo Strati and Guilin Tang and Duose, {Dzifa Y.} and Saradhi Mallampati and Rajyalakshmi Luthra and Patel, {Keyur P.} and Mohammad Hussaini and Mirza, {Abu Sayeef} and Komrokji, {Rami S.} and Stephen Oh and John Mascarenhas and Vesna Najfeld and Vivek Subbiah and Hagop Kantarjian and Guillermo Garcia-Manero and Srdan Verstovsek and Naval Daver",

note = "Publisher Copyright: {\textcopyright} 2017, {\textcopyright} 2017 Informa UK Limited, trading as Taylor & Francis Group.",

year = "2018",

month = jul,

day = "3",

doi = "10.1080/10428194.2017.1397663",

language = "English",

volume = "59",

pages = "1672--1676",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

number = "7",

}

Strati, P, Tang, G, Duose, DY, Mallampati, S, Luthra, R, Patel, KP, Hussaini, M, Mirza, AS, Komrokji, RS, Oh, S, Mascarenhas, J, Najfeld, V, Subbiah, V, Kantarjian, H, Garcia-Manero, G, Verstovsek, S & Daver, N 2018, 'Myeloid/lymphoid neoplasms with FGFR1 rearrangement', Leukemia and Lymphoma, vol. 59, no. 7, pp. 1672-1676. https://doi.org/10.1080/10428194.2017.1397663

TY - JOUR

T1 - Myeloid/lymphoid neoplasms with FGFR1 rearrangement

AU - Strati, Paolo

AU - Tang, Guilin

AU - Duose, Dzifa Y.

AU - Mallampati, Saradhi

AU - Luthra, Rajyalakshmi

AU - Patel, Keyur P.

AU - Hussaini, Mohammad

AU - Mirza, Abu Sayeef

AU - Komrokji, Rami S.

AU - Oh, Stephen

AU - Mascarenhas, John

AU - Najfeld, Vesna

AU - Subbiah, Vivek

AU - Kantarjian, Hagop

AU - Garcia-Manero, Guillermo

AU - Verstovsek, Srdan

AU - Daver, Naval

PY - 2018/7/3

Y1 - 2018/7/3

N2 - Myeloid/lymphoid neoplasms with FGFR1 rearrangement are a rare entity. We present a multicenter experience of 17 patients with FISH-confirmed FGFR1 rearrangement. The clinical presentation at diagnosis included myeloproliferative neoplasm (MPN) in 4 (24%) patients, acute leukemia (AL) in 7 (41%), and concomitant MPN with AL in 6 (35%). The two most frequently observed cytogenetic abnormalities were t(8;13)(p11.2;q12)(partner gene ZMYM2) and t(8;22)(p11.2; q11.2)(BCR). Seventy-eight percent of tested patients had a RUNX1 mutation, of whom all had AL. Overall response rate to frontline therapy was 69%, and 76% of patients subsequently received allogeneic stem cell transplant (ASCT). After a median follow-up of 11 months, median progression-free survival was 15 months and median overall survival was not reached. In conclusion, FGFR1-rearranged hematologic malignancies present with features of MPN and/or AL. FGFR1 and RUNX1 are therapeutic targets for ongoing and future clinical trials.

AB - Myeloid/lymphoid neoplasms with FGFR1 rearrangement are a rare entity. We present a multicenter experience of 17 patients with FISH-confirmed FGFR1 rearrangement. The clinical presentation at diagnosis included myeloproliferative neoplasm (MPN) in 4 (24%) patients, acute leukemia (AL) in 7 (41%), and concomitant MPN with AL in 6 (35%). The two most frequently observed cytogenetic abnormalities were t(8;13)(p11.2;q12)(partner gene ZMYM2) and t(8;22)(p11.2; q11.2)(BCR). Seventy-eight percent of tested patients had a RUNX1 mutation, of whom all had AL. Overall response rate to frontline therapy was 69%, and 76% of patients subsequently received allogeneic stem cell transplant (ASCT). After a median follow-up of 11 months, median progression-free survival was 15 months and median overall survival was not reached. In conclusion, FGFR1-rearranged hematologic malignancies present with features of MPN and/or AL. FGFR1 and RUNX1 are therapeutic targets for ongoing and future clinical trials.

KW - FGFR1 rearrangement

KW - Myeloproliferative neoplasm

KW - RUNX1

KW - acute leukemia

UR - http://www.scopus.com/inward/record.url?scp=85033693826&partnerID=8YFLogxK

U2 - 10.1080/10428194.2017.1397663

DO - 10.1080/10428194.2017.1397663

M3 - Article

C2 - 29119847

AN - SCOPUS:85033693826

SN - 1042-8194

VL - 59

SP - 1672

EP - 1676

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 7

ER -

Myeloid/lymphoid neoplasms with FGFR1 rearrangement

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this